3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Brain Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pain, Postoperative
2
Pain
2
Ovarian Neoplasms
2
Neoplasms
2
Warts
1
Stroke
1
Sepsis
1
Schwannomatosis
1
Prostatic Neoplasms
1
Pleural Effusion
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Cyst
1
Neuroinflammatory Diseases
1
Neurilemmoma
1
Multiple Myeloma
1
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hypoxia
1
Hyperthermia
1
Hemorrhage
1
Glycopyrrolate
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Erectile Dysfunction
1
Colorectal Neoplasms
1
Interventions
Cyclophosphamide
28
Rituximab
23
fludarabine
14
fludarabine phosphate
12
Specimen Handling
11
obinutuzumab
10
ibrutinib
10
Magnetic Resonance Spectroscopy
10
Prednisone
8
Doxorubicin
8
tocilizumab
7
polatuzumab vedotin
7
X-Rays
7
Whole-Body Irradiation
7
Phantoms, Imaging
7
Mycophenolic Acid
7
Etoposide
7
Biopsy
7
venetoclax
6
glofitamab
6
Melphalan
6
Lenalidomide
6
Bendamustine Hydrochloride
6
pirtobrutinib
5
acalabrutinib
5
Vincristine
5
Peripheral Blood Stem Cell Transplantation
5
Nuclear Medicine Department, Hospital
5
Nivolumab
5
Gemcitabine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
Saline Solution
×
90 days
×
Clear all
NCT05645107
2026-04-13
EXCELL
Grifols Therapeutics LLC
Phase 3
Recruiting
386 enrolled